Compare Sanofi SA (SNY) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Verizon Communications Inc — how do they compare? Sanofi SA trades at $43.12 (market cap $104.06B), while Verizon Communications Inc trades at $49.79 (market cap $209.44B). The key difference: Verizon Communications Inc is far larger — about 2× Sanofi SA's market cap, and Verizon Communications Inc is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | VZ | |
|---|---|---|
Market Cap | $104.06B | $209.44B |
Sector | Health | Media |
52-Week High | $52.34 | $51.38 |
52-Week Low | $41.33 | $38.40 |
Enterprise Value | $124.09B | $396.15B |
Dividend Yield | 5.61% | 5.61% |
Volume | — | 22,584,735 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SNY trades at $43.16, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported Q2 2026 EPS of $1.21, beating expectations, and raised its 2026 outlook driven by Dupixent strength. Financials show improved net income of $7.81B in 2025, with a P/E of 22.94 and net margin of 8.09%.
Outlook is mixed: strong drug performance and analyst hold ratings suggest stability, but pipeline setbacks and projected 2026 profit margin decline to 8.09% pose risks. The stock offers a 5.4% dividend yield, trading below sector P/E, presenting value if growth execution offsets challenges.
Verizon (VZ) trades at $50.41, up 0.54% today, with a bullish technical signal and strong fundamental metrics including a 15.63% ROE and 11.64% net margin. Recent earnings beats and a 5%+ dividend yield support investor confidence, while the stock trades below the consensus price target of $49.69. The company's fiber expansion deal with Corning and focus on broadband growth provide positive momentum.
Outlook remains positive with cost discipline and shareholder returns driving value, though high debt levels and competitive pressures pose risks. The stock offers income appeal with growth potential from AI infrastructure investments, but requires monitoring of execution on turnaround initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
